Immunoglobulin repletion during blinatumomab therapy does not reduce the rate of secondary hypogammaglobulinemia and associated infectious risk-Reference-Cited by-同舟云学术

Immunoglobulin repletion during blinatumomab therapy does not reduce the rate of secondary hypogammaglobulinemia and associated infectious risk

Published:2022-05-13 Issue:2 Volume:57 Page:135-143
ISSN:2287-979X
Container-title:Blood Research
language:en
Short-container-title:Blood Res

Author:

Wo Stephanie¹,Levavi Hannah²,Mascarenhas John²,Kremyanskaya Marina²,Navada Shyamala²,Bar-Natan Michal²,Kim Sara S.¹

Affiliation:

1. Department of Pharmacy, The Mount Sinai Hospital, New York, NY, USA

2. Division of Hematology/Oncology, Icahn School of Medicine at The Mount Sinai Hospital, New York, NY, USA

Publisher

The Korean Society of Hematology

Subject

Hematology

Link

http://pdf.medrang.co.kr/BR/2022/057/BR2057-02-135.pdf

Reference23 articles.

1. Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia

2. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies

3. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

4. Adult Acute Lymphoblastic Leukemia

5. National Comprehensive Cancer Network. Acute lymphoblastic leukemia (version 2.2020). Plymouth Meeting, PA: National Comprehensive Cancer Network, 2020 (Accessed November 28, 2020, at https://www.nccn.org/professionals/physician_gls/pdf/all.pdf).

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Blinatumomab in Children with MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia: A Report of 11 Cases;Hematology Reports;2024-06-03

2. Managing infectious challenges in the age of molecular‐targeted therapies for adult hematological malignancies;Transplant Infectious Disease;2024-05-02

3. Blinatumomab in Practice;Current Hematologic Malignancy Reports;2023-12-07

4. Case Report: Blinatumomab as upfront consolidation and maintenance therapy in a pediatric patient with high-risk B-cell acute lymphoblastic leukemia;Frontiers in Oncology;2023-11-01

5. Immunoglobulin replacement in hematological malignancies: a focus on evidence, alternatives, dosing strategy, and cessation rule;Leukemia & Lymphoma;2022-10-11